FMP
Replimune Group, Inc.
REPL
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
11.48 USD
-0.175 (-1.52%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Sushil Patel Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.replimune.comexchange
NASDAQ
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise cause...
CIK
0001737953
ISIN
US76029N1063
CUSIP
76029N106
Address
500 Unicorn Park Drive
Phone
781 222 9600
Country
US
Employee
331
IPO Date
Jul 20, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
REPL Financial Summary
CIK
0001737953
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
76029N106
ISIN
US76029N1063
Country
US
Price
11.48
Beta
1.3
Volume Avg.
732.97k
Market Cap
884.13M
Shares
-
52-Week
4.92-17
DCF
0.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.74
P/B
-
Website
https://www.replimune.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest REPL News
It looks like there's no news available.
